KMT2C and neoplasm: Loss-of-function mutations in the Lysine Demethylase 6A (KDM6A), Lysine Methyltransferase 2C (KMT2C), and Zinc Finger MYM-Type Containing 3 (ZMYM3) are enriched in Group 4 tumors, indicating convergent epigenomic dysregulation in tumor development [36].